The use of allograft and recombinant human bone morphogenetic protein for instrumented atlantoaxial fusions

Brian Hood, D. Kojo Hamilton, Justin S. Smith, Marine Dididze, Christopher Shaffrey, Allan D Levi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background Iliac crest autograft is the historic gold standard for bone grafting, but is associated with a significant patient morbidity. Fusion rates of C1-C2 up to 88.9% using allograft and 96.7% using autologous iliac crest bone graft can be achieved when combined with rigid screw fixation. We sought to determine our fusion rate when combining allograft with recombinant human bone morphogenetic protein-2 (rh-BMP2) and rigid screw fixation.

Methods We reviewed our experience using allograft, bone morphogenetic protein (rh-BMP2) and screw fixation of C1-C2 in 52 patients and examined indications, surgical technique, fusion rates, and complications. In 28 patients, corticocancellous allograft pieces were laid along decorticated bone after a C2 neurectomy was performed. In 24 patients, unicortical iliac crest allograft was precision-cut to fit between the C1 lamina and C2 spinous processes.

Results Fifty-two C1-C2 fusions were performed with allograft, rh-BMP2, and rigid screw fixation. There were 25 female and 27 male patients ranging in age from 6 to 92 years (mean, 65.8 years). Operative indications included trauma (56%), degenerative disease (21%), rheumatoid arthritis (15%), congenital anomalies (6%), and synovial cyst (2%). The mean follow-up was 23.9 ± 2.1 months (range, 2-55 months). The mean dose of rh-BMP2 used for all patients was 4.5 mg (range, 2.2-12 mg). In patients who achieved sufficient follow-up, 100% achieved solid fusion: 45/50 Lenke A, 5/50 Lenke B. There were no known complications attributable to the use of rh-BMP2.

Conclusions The use of small doses of rh-BMP2 added to allograft in addition to rigid screw fixation is a safe and highly effective means of promoting a solid fusion of the atlantoaxial complex and spares the patient the morbidity of iliac crest harvest.

Original languageEnglish
Pages (from-to)1369-1373
Number of pages5
JournalWorld Neurosurgery
Volume82
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Bone Morphogenetic Proteins
Allografts
Synovial Cyst
Morbidity
Bone and Bones
Bone Transplantation
Atlanto-Axial Fusion
Autografts
recombinant human bone morphogenetic protein-2
Rheumatoid Arthritis
Transplants
Wounds and Injuries

Keywords

  • Atlantoaxial allograft
  • Cervical
  • Fusion rh-BMP2

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

The use of allograft and recombinant human bone morphogenetic protein for instrumented atlantoaxial fusions. / Hood, Brian; Hamilton, D. Kojo; Smith, Justin S.; Dididze, Marine; Shaffrey, Christopher; Levi, Allan D.

In: World Neurosurgery, Vol. 82, No. 6, 01.01.2014, p. 1369-1373.

Research output: Contribution to journalArticle

Hood, Brian ; Hamilton, D. Kojo ; Smith, Justin S. ; Dididze, Marine ; Shaffrey, Christopher ; Levi, Allan D. / The use of allograft and recombinant human bone morphogenetic protein for instrumented atlantoaxial fusions. In: World Neurosurgery. 2014 ; Vol. 82, No. 6. pp. 1369-1373.
@article{71c589038b734a338e9e62b3314740fe,
title = "The use of allograft and recombinant human bone morphogenetic protein for instrumented atlantoaxial fusions",
abstract = "Background Iliac crest autograft is the historic gold standard for bone grafting, but is associated with a significant patient morbidity. Fusion rates of C1-C2 up to 88.9{\%} using allograft and 96.7{\%} using autologous iliac crest bone graft can be achieved when combined with rigid screw fixation. We sought to determine our fusion rate when combining allograft with recombinant human bone morphogenetic protein-2 (rh-BMP2) and rigid screw fixation.Methods We reviewed our experience using allograft, bone morphogenetic protein (rh-BMP2) and screw fixation of C1-C2 in 52 patients and examined indications, surgical technique, fusion rates, and complications. In 28 patients, corticocancellous allograft pieces were laid along decorticated bone after a C2 neurectomy was performed. In 24 patients, unicortical iliac crest allograft was precision-cut to fit between the C1 lamina and C2 spinous processes.Results Fifty-two C1-C2 fusions were performed with allograft, rh-BMP2, and rigid screw fixation. There were 25 female and 27 male patients ranging in age from 6 to 92 years (mean, 65.8 years). Operative indications included trauma (56{\%}), degenerative disease (21{\%}), rheumatoid arthritis (15{\%}), congenital anomalies (6{\%}), and synovial cyst (2{\%}). The mean follow-up was 23.9 ± 2.1 months (range, 2-55 months). The mean dose of rh-BMP2 used for all patients was 4.5 mg (range, 2.2-12 mg). In patients who achieved sufficient follow-up, 100{\%} achieved solid fusion: 45/50 Lenke A, 5/50 Lenke B. There were no known complications attributable to the use of rh-BMP2.Conclusions The use of small doses of rh-BMP2 added to allograft in addition to rigid screw fixation is a safe and highly effective means of promoting a solid fusion of the atlantoaxial complex and spares the patient the morbidity of iliac crest harvest.",
keywords = "Atlantoaxial allograft, Cervical, Fusion rh-BMP2",
author = "Brian Hood and Hamilton, {D. Kojo} and Smith, {Justin S.} and Marine Dididze and Christopher Shaffrey and Levi, {Allan D}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.wneu.2013.01.083",
language = "English",
volume = "82",
pages = "1369--1373",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - The use of allograft and recombinant human bone morphogenetic protein for instrumented atlantoaxial fusions

AU - Hood, Brian

AU - Hamilton, D. Kojo

AU - Smith, Justin S.

AU - Dididze, Marine

AU - Shaffrey, Christopher

AU - Levi, Allan D

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background Iliac crest autograft is the historic gold standard for bone grafting, but is associated with a significant patient morbidity. Fusion rates of C1-C2 up to 88.9% using allograft and 96.7% using autologous iliac crest bone graft can be achieved when combined with rigid screw fixation. We sought to determine our fusion rate when combining allograft with recombinant human bone morphogenetic protein-2 (rh-BMP2) and rigid screw fixation.Methods We reviewed our experience using allograft, bone morphogenetic protein (rh-BMP2) and screw fixation of C1-C2 in 52 patients and examined indications, surgical technique, fusion rates, and complications. In 28 patients, corticocancellous allograft pieces were laid along decorticated bone after a C2 neurectomy was performed. In 24 patients, unicortical iliac crest allograft was precision-cut to fit between the C1 lamina and C2 spinous processes.Results Fifty-two C1-C2 fusions were performed with allograft, rh-BMP2, and rigid screw fixation. There were 25 female and 27 male patients ranging in age from 6 to 92 years (mean, 65.8 years). Operative indications included trauma (56%), degenerative disease (21%), rheumatoid arthritis (15%), congenital anomalies (6%), and synovial cyst (2%). The mean follow-up was 23.9 ± 2.1 months (range, 2-55 months). The mean dose of rh-BMP2 used for all patients was 4.5 mg (range, 2.2-12 mg). In patients who achieved sufficient follow-up, 100% achieved solid fusion: 45/50 Lenke A, 5/50 Lenke B. There were no known complications attributable to the use of rh-BMP2.Conclusions The use of small doses of rh-BMP2 added to allograft in addition to rigid screw fixation is a safe and highly effective means of promoting a solid fusion of the atlantoaxial complex and spares the patient the morbidity of iliac crest harvest.

AB - Background Iliac crest autograft is the historic gold standard for bone grafting, but is associated with a significant patient morbidity. Fusion rates of C1-C2 up to 88.9% using allograft and 96.7% using autologous iliac crest bone graft can be achieved when combined with rigid screw fixation. We sought to determine our fusion rate when combining allograft with recombinant human bone morphogenetic protein-2 (rh-BMP2) and rigid screw fixation.Methods We reviewed our experience using allograft, bone morphogenetic protein (rh-BMP2) and screw fixation of C1-C2 in 52 patients and examined indications, surgical technique, fusion rates, and complications. In 28 patients, corticocancellous allograft pieces were laid along decorticated bone after a C2 neurectomy was performed. In 24 patients, unicortical iliac crest allograft was precision-cut to fit between the C1 lamina and C2 spinous processes.Results Fifty-two C1-C2 fusions were performed with allograft, rh-BMP2, and rigid screw fixation. There were 25 female and 27 male patients ranging in age from 6 to 92 years (mean, 65.8 years). Operative indications included trauma (56%), degenerative disease (21%), rheumatoid arthritis (15%), congenital anomalies (6%), and synovial cyst (2%). The mean follow-up was 23.9 ± 2.1 months (range, 2-55 months). The mean dose of rh-BMP2 used for all patients was 4.5 mg (range, 2.2-12 mg). In patients who achieved sufficient follow-up, 100% achieved solid fusion: 45/50 Lenke A, 5/50 Lenke B. There were no known complications attributable to the use of rh-BMP2.Conclusions The use of small doses of rh-BMP2 added to allograft in addition to rigid screw fixation is a safe and highly effective means of promoting a solid fusion of the atlantoaxial complex and spares the patient the morbidity of iliac crest harvest.

KW - Atlantoaxial allograft

KW - Cervical

KW - Fusion rh-BMP2

UR - http://www.scopus.com/inward/record.url?scp=84917735922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917735922&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2013.01.083

DO - 10.1016/j.wneu.2013.01.083

M3 - Article

C2 - 23336983

AN - SCOPUS:84917735922

VL - 82

SP - 1369

EP - 1373

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

IS - 6

ER -